Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas
作者： A. B. Cortot , P. A. Janne
DOI: 10.1183/09059180.00004614
关键词:
摘要: The discovery of epidermal growth factor receptor (EGFR) mutations in nonsmall cell lung cancer (NSCLC) has allowed the identification a subset patients whose tumours are exquisitely sensitive to EGFR tyrosine kinase inhibitors (TKIs). Despite efficacy and superiority TKIs over chemotherapy as first-line therapy, all will ultimately develop progressive disease, with median 9-13 months progression-free survival. A better understanding molecular mechanisms underlying resistance can help design new drugs therapeutic strategies overcome resistance. This been illustrated by generation that effective on T790M mutation, which is most frequent mechanism acquired TKIs. In this article, we address main primary EGFR-mutant NSCLC.
core.ac.uk
paperity.org参考文章(89)
Kang-Yi Su, Hsuan-Yu Chen, Ker-Chau Li, Min-Liang Kuo, James Chih-Hsin Yang, Wing-Kai Chan, Bing-Ching Ho, Gee-Chen Chang, Jin-Yuan Shih, Sung-Liang Yu, Pan-Chyr Yang, Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 30, pp. 433- 440 ,(2012) , 10.1200/JCO.2011.38.3224
Yixuan Gong, Romel Somwar, Katerina Politi, Marissa Balak, Juliann Chmielecki, Xuejun Jiang, William Pao, Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas PLOS Medicine. ,vol. 4, ,(2007) , 10.1371/JOURNAL.PMED.0040294
Daniel B Costa, Balázs Halmos, Amit Kumar, Susan T Schumer, Mark S Huberman, Titus J Boggon, Daniel G Tenen, Susumu Kobayashi, BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations PLOS Medicine. ,vol. 4, pp. 1669- 1680 ,(2007) , 10.1371/JOURNAL.PMED.0040315
I. B. Weinstein, CANCER: Enhanced: Addiction to Oncogenes--the Achilles Heal of Cancer Science. ,vol. 297, pp. 63- 64 ,(2002) , 10.1126/SCIENCE.1073096
Simone Filosto, Cathleen R. Becker, Tzipora Goldkorn, Cigarette Smoke Induces Aberrant EGF Receptor Activation That Mediates Lung Cancer Development and Resistance to Tyrosine Kinase Inhibitors Molecular Cancer Therapeutics. ,vol. 11, pp. 795- 804 ,(2012) , 10.1158/1535-7163.MCT-11-0698
Sreenath V. Sharma, Diana Y. Lee, Bihua Li, Margaret P. Quinlan, Fumiyuki Takahashi, Shyamala Maheswaran, Ultan McDermott, Nancy Azizian, Lee Zou, Michael A. Fischbach, Kwok-Kin Wong, Kathleyn Brandstetter, Ben Wittner, Sridhar Ramaswamy, Marie Classon, Jeff Settleman, A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations Cell. ,vol. 141, pp. 69- 80 ,(2010) , 10.1016/J.CELL.2010.02.027
J. A. Engelman, K. Zejnullahu, C.-M. Gale, E. Lifshits, A. J. Gonzales, T. Shimamura, F. Zhao, P. W. Vincent, G. N. Naumov, J. E. Bradner, I. W. Althaus, L. Gandhi, G. I. Shapiro, J. M. Nelson, J. V. Heymach, M. Meyerson, K.-K. Wong, P. A. Janne, PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib Cancer Research. ,vol. 67, pp. 11924- 11932 ,(2007) , 10.1158/0008-5472.CAN-07-1885
Rafael Rosell, Enric Carcereny, Radj Gervais, Alain Vergnenegre, Bartomeu Massuti, Enriqueta Felip, Ramon Palmero, Ramon Garcia-Gomez, Cinta Pallares, Jose Miguel Sanchez, Rut Porta, Manuel Cobo, Pilar Garrido, Flavia Longo, Teresa Moran, Amelia Insa, Filippo De Marinis, Romain Corre, Isabel Bover, Alfonso Illiano, Eric Dansin, Javier De Castro, Michele Milella, Noemi Reguart, Giuseppe Altavilla, Ulpiano Jimenez, Mariano Provencio, Miguel Angel Moreno, Josefa Terrasa, Jose Muñoz-Langa, Javier Valdivia, Dolores Isla, Manuel Domine, Olivier Molinier, Julien Mazieres, Nathalie Baize, Rosario Garcia-Campelo, Gilles Robinet, Delvys Rodriguez-Abreu, Guillermo Lopez-Vivanco, Vittorio Gebbia, Lioba Ferrera-Delgado, Pierre Bombaron, Reyes Bernabe, Alessandra Bearz, Angel Artal, Enrico Cortesi, Christian Rolfo, Maria Sanchez-Ronco, Ana Drozdowskyj, Cristina Queralt, Itziar de Aguirre, Jose Luis Ramirez, Jose Javier Sanchez, Miguel Angel Molina, Miquel Taron, Luis Paz-Ares, None, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncology. ,vol. 13, pp. 239- 246 ,(2012) , 10.1016/S1470-2045(11)70393-X
David Jackman, William Pao, Gregory J. Riely, Jeffrey A. Engelman, Mark G. Kris, Pasi A. Jänne, Thomas Lynch, Bruce E. Johnson, Vincent A. Miller, Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 28, pp. 357- 360 ,(2010) , 10.1200/JCO.2009.24.7049
Shirish M. Gadgeel, Fadlo R. Khuri, Jeff A. Engelman, Marianna Koczywas, Arun Rajan, Alicyn K. Campbell, Diana Gernhardt, Ana Ruiz-Garcia, Stephen Letrent, Jane Liang, Ian Taylor, Joseph P. O'Connell, Pasi A. Jänne, Karen L. Reckamp, Giuseppe Giaccone, D. Ross Camidge, A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib. Cancer. ,vol. 120, pp. 1145- 1154 ,(2014) , 10.1002/CNCR.28561